Efficacy of IV Azithromycin in Improving Visualization During Esophagogastroduodenoscopy in Patients With Acute Gastrointestinal Bleeding: A DoubleBlind Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250302012

Enrollment

Registered

2025-03-02

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper GI bleeding subject GI bleeding

Interventions

Patients in this group will receive 250 mg IV Azithromycin drip in 60 minutes before the scheduled EGD 30-180 mins to allow the drug to exert its prokinetic effect, promoting gastric emptying and impr

Experimental Drug,Experimental Drug

Azythromycin,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 years and older 2. Present clinical evidence of acute UGIB 3. Stable hemodynamics

Exclusion criteria

Exclusion criteria: 1. History of gastric or upper GI surgery 2. Known allergy or contraindication to erythromycin 3. Pregnancy 4. Use of prokinetic agents within 24 hours 5. Unstable hemodynamics 6. Scheduled for emergency EGD in 2 hours

Design outcomes

Primary

Measure	Time frame
The quality of gastric and duodenal visualization during EGD. 1 hour after injection medication Endoscopic Visualized Gastroduodenal Score (EVS)	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactChanunta HONGTHANAKORN

Bhumibol Adueyadej Hospital

rabbithap@yahoo.com025347341

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026